Neuroprotective Activity of Thioctic Acid in Central Nervous System Lesions Consequent to Peripheral Nerve Injury

<table>Sections of motor area (M1) processed for the immunohistochemical demonstration of myelin basic protein. (a) WKY control Sham-operated rats, (b) control Sham-operated SHRs, (c) control CCI SHRs, (d) CCI SHRs treated with (<svg height="14.85" id="M83" style="vertical-align:-2.22495pt" version="1.1" viewbox="0 0 27.0875 14.85" width="27.0875" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,12.012)"><path d="M535 230h-212v-233h-58v233h-213v50h213v210h58v-210h212v-50z" id="x2B"></path></g><g transform="matrix(.017,-0,0,-.017,10.041,12.012)"><path d="M368 703l-264 -866h-60l265 866h59z" id="x2F"></path></g><g transform="matrix(.017,-0,0,-.017,17.044,12.012)"><path d="M535 230h-483v50h483v-50z" id="x2212"></path></g>
</svg>)-thioctic acid 250 <i>μ</i>mol/kg/day, (e) CCI SHRs treated with (<svg height="14.85" id="M84" style="vertical-align:-2.22495pt" version="1.1" viewbox="0 0 27.0875 14.85" width="27.0875" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,12.012)"><path d="M535 230h-212v-233h-58v233h-213v50h213v210h58v-210h212v-50z" id="x2B"></path></g><g transform="matrix(.017,-0,0,-.017,10.041,12.012)"><path d="M368 703l-264 -866h-60l265 866h59z" id="x2F"></path></g><g transform="matrix(.017,-0,0,-.017,17.044,12.012)"><path d="M535 230h-483v50h483v-50z" id="x2212"></path></g>
</svg>)-thioctic acid 125 <i>μ</i>mol/kg/day, (f) CCI SHRs treated with (+)-thioctic acid 125 <i>μ</i>mol/kg/day, (g) CCI SHRs treated with (−)-thioctic acid 125 <i>μ</i>mol/kg/day, and (h) CCI SHRs treated with pregabalin 300 <i>μ</i>mol/kg/day (H).  Calibration bar: 25 <i>μ</i>m.</table>

BioMed Research International

fig9

Figure 9

Figure 9: Neuroprotective Activity of Thioctic Acid in Central Nervous System Lesions Consequent to Peripheral Nerve Injury 